Document Detail


Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma.
MedLine Citation:
PMID:  23225462     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
BACKGROUND: Although high-dose chemotherapy (HDC) represents the standard of treatment for high-risk neuroblastoma (NBL), the most effective conditioning regimen still remains to be identified.
PATIENTS AND METHODS: Forty-one high-risk NBL entered into local protocol based on induction chemotherapy, surgery and HDC with either etoposide/thiotepa/cyclophophamide (ETC) or i.v. busulfan and L-PAM (Bu/L-PAM).
RESULTS: Thirty-seven patients underwent HDC; 29 with ETC and 8 with Bu/L-PAM. No toxic deaths were recorded. The 5-year progression-free survival (PFS) of patients given ETC was 21% (95% confidence interval CI (9-36%), while PFS for patients given Bu/L-PAM was 88% (95% CI=39-98%) (p<0.05). In multivariate analysis, treatment with the ETC regimen predicted progression/recurrence with a hazard ratio (HR) of 16.8 (p<0.05), as well as MYCN amplification which had an HR of 4.4 (p<0.05).
CONCLUSION: Although the number of studied cases is limited, our data suggest that in high-risk NBL the combination of Bu/L-PAM is superior to the ETC regimen.
Authors:
Maria Antonietta DE Ioris; Benedetta Contoli; Alessandro Jenkner; Maria Debora DE Pasquale; Annalisa Serra; Luigi DE Sio; Rosanna Pessolano; Maria Carmen Garganese; Alessandro Crocoli; Teresa Corneli; Renata Boldrini; Aurora Castellano
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  32     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-10     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  5527-33     Citation Subset:  IM    
Affiliation:
Hematology/Oncology Department, Bambino Gesù Children Hospital, Rome, Italy. deioris@opbg.net.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colore...
Next Document:  Differing impacts of pretransplant serum ferritin and C-reactive protein levels on the incidence of ...